A method of disrupting a bacterial biofilm present on a surface, comprising applying a composition that includes a semi-alkaline protease produced by the fermentation of the fungus Aspergillus melleus (Seaprose) to the bacterial biofilm, wherein application of the composition to the bacterial biofilm disrupts the matrix of the bacterial biofilm.

Certain embodiments of the invention provide a formulation suitable for nasal administration comprising water, a prodrug of a therapeutic agent, and an enzyme that is suitable for intranasal conversion of the prodrug to the therapeutic agent, as well as methods of use thereof.

An egg chalaza hydrolysate, a method for preparing the same and a usage of the same are revealed. An egg chalaza is hydrolyzed by an enzyme to get a hydrolysate solution. The hydrolysate solution is filtered and lyophilized to get an egg chalaza hydrolysate. The egg chalaza hydrolysate includes leucine, arginine, phenylalanine, valine, and lysine. The egg chalaza hydrolysate can reduce fat accumulation and oxidative stress in livers. Thus the egg chalaza hydrolysate is applied to prepare a composition for liver protection.

Fungal protease compositions, and more particularly, proteolytic enzyme mixtures comprising a plurality of Aspergillus proteases are provided. The disclosure also relates to protein hydrolysates, food and beverage products and dietary supplements produced using these proteolytic enzyme mixtures, and methods of making and using the same.

The present invention relates to a new drug delivery strategy based on prodrug conversion, in which a water-soluble prodrug and its converting enzyme are co-delivered and at a point of administration such as the nasal or buccal mucosa. Enzymatic conversion of the prodrug produces drug in concentrations exceeding the drug's thermodynamic solubility, or saturation level. The supersaturated drug crosses the mucosal membrane quickly, as a result of its high thermodynamic activity, prior to crystallization. This strategy is particularly useful when fast action is required, for example in preventing or responding rapidly to Status Epilepticus (SE) or other central nervous system conditions such as migraine.

Wound debridement compositions containing the proteolytic enzyme Seaprose and use of such compositions in wound treatment for the enzymatic debridement of wounds.

The present invention relates to a new drug delivery strategy based on prodrug conversion, in which a water-soluble prodrug and its converting enzyme are co-delivered and at a point of administration such as the nasal or buccal mucosa. Enzymatic conversion of the prodrug produces drug in concentrations exceeding the drug's thermodynamic solubility, or saturation level. The supersaturated drug crosses the mucosal membrane quickly, as a result of its high thermodynamic activity, prior to crystallization. This strategy is particularly useful when fast action is required, for example in preventing or responding rapidly to Status Epilepticus (SE) or other central nervous system conditions such as migraine.

An egg chalaza hydrolysate, a method for preparing the same and a usage of the same are revealed. An egg chalaza is hydrolyzed by an enzyme to get a hydrolysate solution. The hydrolysate solution is filtered and lyophilized to get an egg chalaza hydrolysate. The egg chalaza hydrolysate includes leucine, arginine, phenylalanine, valine, and lysine. The egg chalaza hydrolysate can reduce fat accumulation and oxidative stress in livers. Thus the egg chalaza hydrolysate is applied to prepare a composition for liver protection.

Novel fungal enzyme compositions, and more particularly, enzyme mixtures comprising a plurality of fungal enzymes (e.g., from Aspergillus and Candida) are provided. The disclosure further relates to dietary supplements, foods and beverages containing these enzyme mixtures, and methods of making and using the same.

Certain embodiments of the invention provide a formulation suitable for nasal administration comprising water, a prodrug of a therapeutic agent, and an enzyme that is suitable for intranasal conversion of the prodrug to the therapeutic agent, as well as methods of use thereof.